Q1 2017 13F Holders as of 3/31/2017
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
117M
-
Number of holders
-
107
-
Total 13F shares, excl. options
-
37.3M
-
Shares change
-
+10.4M
-
Total reported value, excl. options
-
$788M
-
Value change
-
+$211M
-
Put/Call ratio
-
0.22
-
Number of buys
-
70
-
Number of sells
-
-49
-
Price
-
$21.15
Significant Holders of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) as of Q1 2017
144 filings reported holding CHRS - Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share as of Q1 2017.
Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) has 107 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 37.3M shares
of 117M outstanding shares and own 31.87% of the company stock.
Largest 10 shareholders include FMR LLC (7.67M shares), Kohlberg Kravis Roberts & Co. L.P. (3.06M shares), BlackRock Inc. (2.84M shares), VANGUARD GROUP INC (2.21M shares), JPMORGAN CHASE & CO (1.63M shares), Partner Fund Management, L.P. (1.5M shares), WELLINGTON MANAGEMENT GROUP LLP (1.27M shares), CARLSON CAPITAL L P (1.21M shares), STATE STREET CORP (1.12M shares), and ORBIMED ADVISORS LLC (1.08M shares).
This table shows the top 107 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.